risk factors for plt
Download
Skip this Video
Download Presentation
Risk factors for ↓ PLT

Loading in 2 Seconds...

play fullscreen
1 / 50

Risk factors for ↓ PLT - PowerPoint PPT Presentation


  • 113 Views
  • Uploaded on

Risk factors for ↓ PLT. Idiopathic Thrombocytopenic purpura (ITP): bleeding disorder, immune system destroys PLTs Thrombotic Thrombocytopenic disorder (TTP): blood disorder causing blood clots to form in small blood vessels around body→ ↓ PLT Hypercoagualtion disorder (DIC, Thrombosis)

loader
I am the owner, or an agent authorized to act on behalf of the owner, of the copyrighted work described.
capcha
Download Presentation

PowerPoint Slideshow about ' Risk factors for ↓ PLT' - pandora-hood


An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.


- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript
risk factors for plt
Risk factors for ↓ PLT
  • Idiopathic Thrombocytopenic purpura (ITP): bleeding disorder, immune system destroys PLTs
  • Thrombotic Thrombocytopenic disorder (TTP): blood disorder causing blood clots to form in small blood vessels around body→ ↓ PLT
  • Hypercoagualtion disorder (DIC, Thrombosis)
  • Hypocoagulation disorder (Liver Dz, Vitamin K deficiency)
  • Chemotherapy—nadir day+7-14 recovery within 2-6 weeks
  • Radiation tx
  • Medications( ASA, digoxin, furosemide, phenytoin, quinidine, sulfonamide, tetracycline)
mgmt thrombocytopenia
Mgmt Thrombocytopenia
  • PLT transfusions PLT<10,000
  • Colony stimulating factors, eg IL 11 (Neumega)
  • Steroids
  • Progesterone ↓ menstrual bleeding
nursing interventions
Nursing interventions
  • Avoid tight BP cuffs when PLT<20,000
  • Avoid invasive procedures
  • Avoid sharp objects/no barefoot
  • Apply firm pressure to venipuncture sites for 5 minutes
  • Treat nose bleeds with high fowler’s position-icepack
  • Prevent constipation
  • Encourage soft toothbrushes
why do we evaluate wbc
Why do we evaluate WBC?
  • To assess body\'s response to significant bacterial insult, such as appendicitis, Pelvic inflammatory disease, pneumonia, pyelonephritis, and SEPSIS
white blood cells
WHITE BLOOD CELLS
  • Segmented Neutrophil (60%)
  • Lymphocytes(30%)
  • Monocytes(6%)
  • Eosinophils(3%)
  • Basophils(1%)
segmented neutrophil
SEGMENTED NEUTROPHIL
  • 1ST line of defense
  • Normal 50-70%
  • Survive 1-2 DAYS
lymphocytes
LYMPHOCYTES
  • 2 Types by appearance: Large granular and small
  • Large granular are NK cells
  • Small are T & B cell
  • T cell mediated immunity
  • B cell humoral immunity
monocyte
MONOCYTE
  • 5-10 % Circulating WBCs
  • When stimulated become Macrophages and dentritic cells in the tissue
  • Clean up the debris
eosinophil
EOSINOPHIL
  • 1-5% Circulating WBCS
  • Involved in parasitic infections
  • Involved with mechanism associated with allergy and asthma
  • ↑In case of w.w.w.
basophil
BASOPHIL
  • < 1% circulating WBCS
  • Involved with allergic and inflammatory response
  • Release histamines and cytokines
hematological symptoms1
Hematological Symptoms
  • Neutropenia—defined as ANC<1000/mm3
  • Anemia--↓RBC & Hgb
  • Thrombocytopenia—low PLT <100,000
  • Leukopenia—decrease in WBC, below the lower limit
  • Pancytopenia-an abnormal deficiency in all blood cells, RBC, WBC, & PLT; usually associated with bone marrow tumor or with aplastic anemia)
risk factors for febrile neutropenia
Risk factors for febrile neutropenia
  • Previous Hx Chemo/Type of chemo/prior radiation Tx
  • Age>65/ female gender
  • Poor nutritional status
  • Advanced cancer and bone marrow involvement
  • ↑LDH, ↓Hgb
  • Leukemia/lymphoma/lung cancer
  • Open wounds
  • DM
  • COPD
prevention of neutropenia
Prevention of Neutropenia
  • Growth stimulating factors activate production of bone marrow cells. It can be given prophylactically or therapeutically
  • BMT give GCSF on day+4 of stem cell SCT
  • GCSF-/filgrastim 5mcg/kg
  • Pegfilgrastim--Neulasta 6mcg/kg
neutropenic precautions
Neutropenic Precautions
  • Limit exposure of pts to infections
  • Hand washing ↓spread
  • Avoid crowds
  • Avoid fresh fruits /vegetables/flowers
  • Avoid caring for animals esp. cleaning excretes
  • Avoid gardening
infections
Infections
  • Mechanical barriers—skin, mucous membranes
  • Chemical barriers-pH of tissues
  • Inflammatory and immune responses
risks of infections
Risks of Infections
  • High risk
  • Intermediate risk
  • Low risk
high risk for infection
High Risk for infection
  • Allogeneic BMT
  • Acute Leukemia\'s
  • GVHD tx ↑dose steroids
  • Neutropenic lasting >10 days
  • Break in skin/mucosal barrier
  • Prolonged ABX or steroid use
  • Poor nutrition
  • Invasive procedure
  • Poor personal hygiene
intermediate risks for infections
Intermediate Risks for infections
  • Autologous BMT
  • Lymphoma/MM/CLL
  • Neutropenic anticipated to last >7-10 days
low risk for infections
Low Risk for infections
  • Standard Chemotherapy
  • Neutropenia <7 days
pt and ptt
PT AND PTT
  • PT (PROTIME) Test the extrinsic pathway
  • PTT Tests the intrinsic pathway
  • COUMADIN (WARFARIN) Affects the Vitamin K factors (II,VII,IX,X ) of which factor VII is the most labile
  • Hemophilia is a factor VIII deficiency
  • INR: Method for standardizing Protimes. It is a ration of tested results : control
coagulation products
COAGULATION PRODUCTS
  • Fresh Frozen Plasma
  • Cryoprecipitate: Factor VIII, Fibrinogen
  • Activated Products: Factor IX
chemistry tests
Chemistry Tests
  • Liver Function Studies
  • Renal Function
  • Electrolytes—Na, K, Ca, Mg, Po4, Co2
liver function
LIVER FUNCTION

Hepatocelluar Enzymes:

  • AST (ASPARTATE AMINOTRANSFERASE)
  • ALT (ALANINE AMINOTRANSFERASE)
  • SGGT (very specific)
  • LDH (Lactate Dehydrogenase)
liver function1
LIVER FUNCTION

ALKALINE PHOSPHATASE-AP not specific to liver

AP= LARGE COMPONENT IN BONE

BILIRUBIN -2 TYPES DIRECT OR CONGUGATED AND INDIRECT OR UNCONGUGATED.

  • AP / BILIRUBIN the first enzymes to rise with liver GVHD
  • INDIRECT BILIRUBIN associated with hemolysis
slide26
LDH
  • Nearly every type of cancer, as well as many other diseases, can cause LDH levels to be ↑, cannot be used to dx a particular type of cancer.
  • LDH levels can be used to monitor treatment of some cancers, including testicular cancer, Ewing\'s sarcoma, non-Hodgkin\'s lymphoma, and some types of leukemia
  • Elevated LDH levels can be caused by a number of noncancerous conditions, including heart failure, hypothyroidism, anemia, and lung or liver disease.
renal
RENAL
  • BUN (BLOOD UREA NITROGEN) Elevated with: Kidney dysfunction, Dehydration, excess protein in blood such as TPN, High protein diet, GI bleeding
  • Creatinine: chemical waste is generated from muscle metabolism. Creatinine is produced from creatine, a molecule of major importance for energy production in muscles. Creatinine is transported through the bloodstream to the kidneys. The kidneys filter out most of the creatinine and dispose of it in the urine.
creatinine cont
CREATININE CONT.
  • The ratio of BUN : creatinine determines renal dysfunction VS pre-renal dysfunction such as dehydration.
  • CALCULATED CREAT. CLEARANCE:

in ml/min---CRCL=(140-AGE) x ideal B.W./Scr. x 72 (x 0.85 for females)

electrolytes
ELECTROLYTES
  • SODIUM
  • POTASSIUM
  • CALCIUM
  • PHOSPHORUS
  • MAGNESIUM
  • CO2
sodium potassium
SODIUM/POTASSIUM
  • SODIUM /POTASSIUM MEMBRANE PUMP
calcium phosphorus
CALCIUM/PHOSPHORUS
  • DIRECT INTERACTION
  • IF GIVEN CONCOMBINETLY: NaPO4 + CaCO3 =
calcium
CALCIUM
  • Calcium in plasma is bound to Albumin. If Albumin is low, you get a falsely low serum calcium.
  • 2 ways to get a more accurate Calcium:

IONIZED CALCIUM CORRECTED CALCIUM

  • CORRECTED Calcium: [(4.0 – serum alb) x 0.8 ] + s Ca = corrected Ca
magnesium
MAGNESIUM
  • Very important for Cardiac, Nervous and GI systems.
  • Interacts with calcium and Potassium.
  • Difficult to get a Normal serum level of Potassium if Mg is low.
slide34
CO2
  • Gives a rough idea of pH and buffer system in blood
  • Infections typically have low venous CO2
bone marrow biopsy aspirate
Bone marrow Biopsy-aspirate
  • Used in Identi. metastatic Dz, esp hematological malignancies
  • Assess iron stores
  • Assess megaloblastic maturation, in Vit B12 and folate deficiencies or in MDS
  • Assess fat atrophy, aplasia or fibrosis
other tests done in hem onc
Other tests done in Hem/Onc
  • Fractionated bilirubin—to differentiate cause of hyperbilirumia
  • Stool guaiac--? bleeding
  • Coombe’s test—direct/indirect
  • Haptoglobin level—to detect hemolytic anemia
  • Hgb electropheresis----
microbiology
MICROBIOLOGY
  • BACTERIA
  • VIRUS
  • FUNGAL/YEAST
  • PROTOZOAN
bacteria
BACTERIA
  • CATAGORIZED BY SHAPE AND STAINING PROPERTIES
  • GRAM’S STAIN
  • SHAPES ARE COCCI, RODS, AND SPIROCHETES
bacterial shapes
COCCI

RODS

SPIROCHETES

BACTERIAL SHAPES
gram s stain
GRAM’S STAIN
  • INTERACTS WITH THE BACTERIAL MEMBRANE AND STAINS IT EITHER BLUE OR RED
  • BLUE IS GM (+)
  • RED IS GM (-)
gram positive
GRAM POSITIVE
  • COCCI: 1. STAPHALOCOCCUS EITHER COAGULASE (-) OR (+) COAG NEG=STAPH EPID. COAG POS= STAPH AUREUS 2. STREP, ENTEROCOCCUS
  • RODS: BACILLUS, LISTERIA, CORYNEBACTERIA DIPTHERIA
gram negative
GRAM NEGATIVE
  • COCCI: NEISSERIA, MORAXELLA, ACINETOBACTER
  • RODS: E.COLI, PSEUDOMONAS, SHIGELLA, SALMONELLA, KLEBSIELLA, PROTEUS, ENTEROBACTER, VIBRIO
fungus
FUNGUS
  • MOLDS: ASPERGILLUS , MUCOR,
  • YEAST AND YEAST-LIKE: CANDIDA, TORULOPSIS, HISTOPLASMOSIS, CRYPTOCOCCUS, BLASTO.
virus
VIRUS
  • CYTOMEGALOVIRUS
  • EPSTEIN-BAR
  • BK
  • ADENOVIRUS
  • INFLUENZA A & B
  • PARAINFLUENZA
  • RSV
pneumocystis carinii
PNEUMOCYSTIS CARINII
  • PREVIOUSLY CONSIDERED A PROTOZOAN BUT NOW IN FUNGUS CLASS
references
References
  • Demetri, G. (2001) Anemia and its functional consequences in cancer pts, current challenges in management & prospects for improving therapy. British Journal of Cancer,84,31-37
  • Dessypris, E, Erythropoiesis (1988). Lee G R, Foster J, Lukens J, Wintrobe M M, eds.Wintrobe’s clinical hematolology. Pa: Lippincott Williams & Williams 1998. 169-192.
  • Ludwig H, & Strasser K.(2001) Symptomatology of anemia. Seminars in oncology, 28, 7-10
  • Means, R. (1999). The anemias of chronic disorders. Lee GR, Foerster J, Lukens J, Paraskeras F, Greer J P, Rodgers GM, eds. WIntrobe’s Clinical hematolgoy.10th ed, Pa. Lippincott Williams & Wilkin;1999:1011-1021
  • National Comprehensive Cancer Network (2007). Cancer and treatment related anemias, version 3.2007
ad